Back to top
more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$68.10 USD

68.10
302,375

-0.29 (-0.42%)

Updated Sep 17, 2025 12:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is It Wise to Retain Henry Schein (HSIC) in Your Portfolio Now?

by Zacks Equity Research

Robust acquisitions and a widespread distribution network bode well for Henry Schein's (HSIC) operations.

Zacks Equity Research

Henry Schein (HSIC) Banks on Strategic Buyouts Amid Macro Issues

by Zacks Equity Research

Henry Schein's (HSIC) revenue growth is supported by niche acquisitions and partnerships.

Indrajit Bandyopadhyay headshot

4 Stocks to Buy Amid Dental Supplies Industry Challenges

by Indrajit Bandyopadhyay

Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.

Zacks Equity Research

What's in Store for Patterson Companies (PDCO) in Q4 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.

Zacks Equity Research

Here's Why Henry Schein (HSIC) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Henry Schein (HSIC) Down 4.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Henry Schein (HSIC) Banks on Global Expansion Amid Macro Issues

by Zacks Equity Research

Within the Dental business, Henry Schein (HSIC) is aiming to deliver customized solutions, leveraging market insights and technological advancements.

Zacks Equity Research

Here's Why Henry Schein (HSIC) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why Henry Schein (HSIC) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC), owing to strategic acquisitions and potential in Henry Schein One.

Zacks Equity Research

Henry Schein (HSIC) Extends Partnership With Special Olympics

by Zacks Equity Research

Henry Schein's (HSIC) extended collaboration with Special Olympics is likely to promote wellness and health education for athletes with ID around the world.

Zacks Equity Research

Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's What Key Metrics Tell Us About Henry Schein (HSIC) Q1 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Henry Schein (HSIC) Tops Q1 Earnings, Lowers '24 Sales View

by Zacks Equity Research

Henry Schein's (HSIC) first-quarter performance reflects a strong recovery from last year's cyber incident.

Zacks Equity Research

Henry Schein (HSIC) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Henry Schein (HSIC) delivered earnings and revenue surprises of 11.11% and 1.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Henry Schein (HSIC) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Henry Schein (HSIC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

Zacks Equity Research

West Pharmaceutical Services (WST) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 20.93% and 3.27%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Align Technology (ALGN) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Align Technology (ALGN) delivered earnings and revenue surprises of 8.08% and 2.62%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Henry Schein (HSIC) Gears Up for Q1 Earnings: Factors to Note

by Zacks Equity Research

Henry Schein's (HSIC) first-quarter 2024 results are likely to indicate a strong sales recovery post last year's cybersecurity incident.

Zacks Equity Research

Henry Schein (HSIC) Global Presence Aids, Macroeconomic Woes Stay

by Zacks Equity Research

Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.

Zacks Equity Research

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Favorable Dental business trends and expansion efforts through acquisitions and partnerships bode well for Henry Schein (HSIC).

Zacks Equity Research

Henry Schein (HSIC) Buys TriMed to Expand in Orthopedic Space

by Zacks Equity Research

According to Henry Schein (HSIC), the upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion.

Zacks Equity Research

Why Is Henry Schein (HSIC) Down 1.8% Since Last Earnings Report?

by Zacks Equity Research

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Compared to Estimates, Henry Schein (HSIC) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Henry Schein (HSIC) Q4 Earnings Miss, Operating Margin Down

by Zacks Equity Research

Henry Schein (HSIC) posts lower-than-expected earnings and revenues in the fourth quarter of 2023.